5.Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Stoffwechselzentrum Rhein-Pfalz, Belchenstraße 1-5, 69163, Mannheim, Germany.
Clin Res Cardiol. 2021 Mar;110(3):313-322. doi: 10.1007/s00392-020-01732-8. Epub 2020 Aug 25.
Transcatheter aortic valve implantation (TAVI) is an accepted treatment approach of aortic stenosis. In the beginning, this technique was executed in high-risk patients only. Today, intermediate-risk patients are also amenable for TAVI, as long as the transfemoral approach is chosen. Numerous predictors have been identified that could lead to periprocedural complications and are defined by patient co-morbidities as well as being inherent to the technical approach. Although vascular complications and postinterventional paravalvular regurgitation have been minimized over the past years by revised technologies and techniques, there is a prevailing individual risk brought about by the specific pathophysiology of the cardiorenal syndrome.
经导管主动脉瓣植入术(TAVI)是一种已被认可的治疗主动脉瓣狭窄的方法。起初,该技术仅适用于高危患者。如今,只要选择经股动脉入路,中危患者也可接受 TAVI。许多预测因素已被确定,这些因素可能导致围手术期并发症,其定义既与患者合并症有关,也与技术方法固有相关。尽管近年来通过改进技术和技术使血管并发症和介入后瓣周漏的发生率降到了最低,但心脏-肾脏综合征的特定病理生理学带来了普遍的个体风险。